Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Pulmonology›Condition·Updated Jul 11, 2026·v1

Sarcoidosis

Sarcoidosis is a multisystem granulomatous disease with a variable course from spontaneous remission to progressive organ failure. Diagnosis rests on histology and exclusion of mimics. Treatment is guided by symptoms and organ threat; methotrexate is now a validated first-line alternative to prednisone. Infliximab is effective for refractory cardiac and neurologic disease. Prognosis is generally good for stage I, but cardiac and advanced pulmonary involvement confer significant mortality.

Moderate Evidence99 references·9,118 words·37 min read·v1
sarcoidosispulmonologygranulomatous diseaseinterstitial lung diseaseLöfgren syndromecardiac sarcoidosisneurosarcoidosis

Quick Reference

RxDrug of choiceMethotrexate 10-15 mg weekly or prednisone 0.5-1 mg/kg/day (first-line pulmonary); infliximab 5 mg/kg IV for refractory disease
AltAlternativesAzathioprine, mycophenolate mofetil, leflunomide, hydroxychloroquine, adalimumab
⊘AvoidNon-dihydropyridine CCBs (diltiazem, verapamil) in cardiac sarcoidosis; mycophenolate and methotrexate in pregnancy
DxTest of choiceBiopsy of most accessible site (EBUS-IFB or EBUS-TMC for mediastinal lymphadenopathy)
ScKey scoreScadding radiographic staging (I-IV) for pulmonary sarcoidosis
→When to referCardiac involvement (arrhythmia, heart failure), neurosarcoidosis, refractory disease, severe ocular sarcoidosis
Sarcoidosis is a diagnosis of exclusion; treat with corticosteroids or methotrexate first-line, escalate to infliximab for refractory disease.
Sarcoidosis is a multisystem granulomatous disease of unknown etiology, most commonly affecting the lungs and mediastinal lymph nodes, with a highly variable course from spontaneous remission to progressive organ failure. Diagnosis requires histologic confirmation of non-caseating granulomas after excluding tuberculosis, fungal infection, and lymphoma. Treatment is indicated for symptomatic or organ-threatening disease; the PREDMETH trial establishes methotrexate as a noninferior first-line alternative to prednisone, shifting the paradigm toward corticosteroid-sparing strategies. For refractory neurologic and cardiac involvement, infliximab is the preferred biologic, achieving high response rates and lower relapse compared to cyclophosphamide or methotrexate alone. Prognosis depends on Scadding stage, race, and organ involvement; cardiac sarcoidosis carries a 1-year mortality of 12.9%.

Overview and Recommendations

Background

  • •Sarcoidosis is a multisystem granulomatous disease of unknown etiology, defined by non-caseating granulomas on histology, with a worldwide prevalence ranging from 10 to 80 per 100,000 and a lifetime incidence of 1-2% in affected populations. The lungs and mediastinal lymph nodes are involved in >90% of cases, but the disease can affect any organ, including the heart, nervous system, skin, and eyes.
  • •The clinical spectrum spans from incidental hilar adenopathy ( stage I) to progressive pulmonary fibrosis (stage IV) and life-threatening cardiac or neurologic involvement. Approximately 50-60% of patients experience spontaneous remission within 2-5 years, but the remainder develop chronic, relapsing disease requiring long-term therapy.
  • •Pathogenesis reflects a Th1/Th17-driven immune response to an unidentified antigen in a genetically susceptible host, with HLA-DRB1 alleles and NOD2 mutations ( ) as key genetic risk factors. The immunologic cascade involves macrophage activation, TNF-α and IFN-γ secretion, and granuloma formation, which can lead to fibrosis and organ dysfunction.
  • •Prognosis varies widely: stage I carries an ~80% chance of spontaneous remission, while stage IV almost never resolves. Sarcoidosis-associated heart failure has a 1-year mortality of 12.9%, significantly worse than dilated cardiomyopathy (HR 1.51). Black race and advanced radiographic stage are independent predictors of relapse after treatment reduction.

Evaluation

  • •Suspect sarcoidosis in any patient with bilateral hilar lymphadenopathy on chest imaging, especially if accompanied by uveitis, erythema nodosum, or unexplained dyspnea and cough. Ask about occupational exposures (silica, pesticides, mould, World Trade Center dust) and a family history of sarcoidosis or immune-mediated diseases.
  • •Examine for cutaneous lesions: lupus pernio (violaceous plaques on nose/ears) suggests chronic fibrotic disease; erythema nodosum (tender red nodules on shins) points to acute . Perform a full ophthalmologic exam, including slit lamp, to detect uveitis.
  • •Order chest radiography with : stage 0 (normal), I (BHL alone), II (BHL + infiltrates), III (infiltrates alone), IV (fibrosis). This provides a crude prognostic framework. High-resolution CT (HRCT) better defines parenchymal involvement and guides biopsy.
  • •Obtain histologic confirmation via biopsy of the most accessible involved site. For mediastinal lymphadenopathy, endobronchial ultrasound-guided intranodal forceps biopsy (EBUS-IFB) or transbronchial mediastinal cryobiopsy (EBUS-TMC) have the highest diagnostic yield (RR 3.50 vs. conventional TBLB). Endomyocardial biopsy has limited sensitivity (~22%) for cardiac sarcoidosis.
  • •Rule out alternative causes of granulomatous inflammation: tuberculosis (AFB smear, culture, PCR, IGRA), fungal infections, berylliosis (beryllium lymphocyte proliferation test), lymphoma (biopsy for Reed-Sternberg cells), and . In the setting of biologic therapy, consider drug-induced sarcoidosis-like reaction (DISR) from anti-TNF, anti-IL-6, or anti-IL-4/IL-13 agents.
  • •Perform baseline laboratory studies: serum calcium (hypercalcemia in 10-20%), creatinine and urinalysis for renal involvement, and consider ACE and soluble IL-2 receptor (sIL-2R) as markers of disease activity, though they lack specificity. Obtain ECG and high-sensitivity troponin if cardiac involvement is suspected.
  • •In suspected cardiac sarcoidosis, order cardiac MRI with late gadolinium enhancement (LGE) and FDG-PET/CT to detect active inflammation and fibrosis. An ICD is indicated for sustained ventricular arrhythmias or LVEF ≤35%. Electroanatomic mapping-guided biopsy can improve endomyocardial yield.
  • •For neurosarcoidosis, perform MRI brain/spine with gadolinium; characteristic findings include expansile, homogeneously enhancing lesions in the infundibulum and hypothalamus. CSF analysis shows lymphocytic pleocytosis and elevated protein; oligoclonal bands may be present. Consider skin biopsy for small fiber neuropathy if symptoms of pain, dysautonomia, or fatigue are present.
  • •Apply the ATS/ERS/WASOG diagnostic criteria: compatible clinical/radiographic picture, histologic evidence of non-caseating granulomas, and exclusion of alternative diagnoses. A presumptive diagnosis can be made in classic without biopsy.
  • •Also consider the differential diagnosis of uveitis, including infectious causes (TB, syphilis, toxoplasmosis) and noninfectious conditions ( , ). In young children, differentiate from (NOD2 mutation, early-onset arthritis, uveitis, rash).

Management

  • •Initiate treatment only for symptomatic or organ-threatening disease; asymptomatic Scadding stage I disease with stable lung function can be observed with reassessment every 3-6 months.
  • •For pulmonary sarcoidosis requiring treatment, start either prednisone 0.5-1 mg/kg/day (typical 20-40 mg/day) OR methotrexate 10-15 mg once weekly (oral or subcutaneous). The trial (2025) showed methotrexate is noninferior to prednisone for improving FVC at 24 weeks, with different side-effect profiles: prednisone causes weight gain, insomnia, hyperglycemia; methotrexate causes nausea, fatigue, liver enzyme elevation.
  • •Taper prednisone to the lowest effective dose, aiming for ≤5-10 mg/day maintenance. For cardiac sarcoidosis, a maintenance dose of 5-10 mg/day is associated with better survival than doses <5 mg/day or >10 mg/day. Re-escalation in the low-dose group is particularly harmful (HR 19.41).
  • •Add a steroid-sparing agent if prednisone cannot be tapered below 5-10 mg/day within 3-6 months. Options include azathioprine (50-200 mg/day), mycophenolate mofetil (500-1500 mg BID), or leflunomide (10-20 mg/day). Hydroxychloroquine (200-400 mg/day) is preferred for cutaneous sarcoidosis.
  • •For refractory or severe disease, initiate infliximab 5 mg/kg IV at weeks 0, 2, and 6, then every 4-8 weeks. Infliximab achieves 100% response in neurosarcoidosis with a 6% relapse rate (vs. 56% with cyclophosphamide, 38% with methotrexate). Adalimumab 40 mg SC weekly or every other week is an alternative.
  • •Use infliximab as first-line biologic for cardiac sarcoidosis with active inflammation on FDG-PET; it increases LVEF and reduces prednisone dose at 6 and 12 months. Monitor for paradoxical sarcoidosis-like reactions, as anti-TNF agents can also induce granulomatous inflammation.
  • •Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in cardiac sarcoidosis as they exacerbate heart failure. In pulmonary sarcoidosis, avoid high-dose corticosteroids for prolonged periods without steroid-sparing agents.
  • •For neurosarcoidosis, combination therapy with corticosteroids and an immunosuppressant (e.g., methotrexate or infliximab) reduces relapse from 40% to 16% compared with steroids alone. Cyclophosphamide (500-750 mg/m² IV monthly) is reserved for rapidly progressive or refractory cases but carries higher infection risk.
  • •In renal sarcoidosis, standard oral prednisone (0.5-1 mg/kg/day) is sufficient; intravenous methylprednisolone pulse offers no additional benefit. Monitor serum creatinine and calcium closely.
  • •For ocular sarcoidosis, start with topical corticosteroids for anterior uveitis; systemic immunosuppression (methotrexate, infliximab) is required for posterior uveitis or refractory disease.
  • •For cutaneous sarcoidosis, use topical or intralesional corticosteroids for localized lesions; hydroxychloroquine is first-line for widespread disease. TNF inhibitors are effective for lupus pernio.
  • •Monitor treatment response: pulmonary, FVC and DLCO every 3-6 months, HRCT at 6-12 months; cardiac, FDG-PET at 6-12 months to guide therapy; neurologic, MRI with gadolinium at 6 months. A successful response is defined as improvement in FVC ≥5 percentage points, resolution of PET activity, or prednisone dose ≤5 mg/day.
  • •Discontinue immunosuppression after sustained remission for 12-24 months; relapse occurs in 39% overall, with higher risk in Black patients (OR 2.48) and advanced radiographic stages (OR 1.73-2.83). In cardiac sarcoidosis, methotrexate can be safely discontinued in 91.7% after mean 44.6 months of therapy.
  • •Refer to cardiology for cardiac sarcoidosis (ICD evaluation, arrhythmia management), to neurology for neurosarcoidosis, to ophthalmology for ocular disease, and to a sarcoidosis specialist for refractory or complex cases.
  • •For patients with small fiber neuropathy, consider low-dose dexamethasone (1 mg daily) or exercise training (40 min cycling twice weekly) to improve fatigue and quality of life.

Board Review — High Yield

  • •Löfgren syndrome, Erythema nodosum, bilateral hilar lymphadenopathy, arthritis; good prognosis, may not require biopsy.
  • •PREDMETH trial, Methotrexate is noninferior to prednisone for first-line pulmonary sarcoidosis (FVC improvement ~6% at 24 weeks).
  • •Infliximab, First-line biologic for neurosarcoidosis; 100% response rate at 12 months, 6% relapse vs 56% with cyclophosphamide.
  • •Scadding stage I, ~80% spontaneous remission; stage IV, <10% remission, requires treatment.
  • •Cardiac sarcoidosis, Suspect in young adults with unexplained AV block, VT, or HF with preserved EF; order CMR and FDG-PET.
  • •Relapse after treatment reduction, 39% overall; higher in Black patients (OR 2.48) and advanced radiographic stages.
  • •Rituximab, Fails in 73.7% of neurosarcoidosis; limited role.
  • •Dupilumab-induced sarcoidosis-like reaction, Consider in pediatric patients on dupilumab with uveitis, optic neuritis, or hilar adenopathy.

Deep Dive — Evidence Details

References

  1. [1]

    Li SP, Luo Y, Liu XB et al.. “Comparative diagnostic performance of advanced endoscopic techniques in suspected sarcoidosis: A systematic review and network meta-analysis.” Pulmonology (2026). PMID: 41944054 ↗

    L1SR_OBSCited in: Definition and Classification, Diagnosis and Diagnostic Workup, Organ-Specific Management
  2. [2]

    Bechman K, Biddle K, Miracle A et al.. “Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis.” Thorax (2025). PMID: 40393718 ↗

    L1SR_OBSCited in: Definition and Classification, Management Overview and Indications for Treatment, Pharmacologic Therapy
  3. [3]

    Güvenc TS, Hasdemir H, Abshir A et al.. “Differentiating Cardiac Sarcoidosis from Arrhythmogenic Right Ventricular Cardiomyopathy: A Systematic Review.” Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2025). PMID: 40273901 ↗

    L2SR_OBSCited in: Definition and Classification, Differential Diagnosis
  4. [4]

    Maccora I, Wouters C, Rosè CD et al.. “Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis.” Journal of autoimmunity (2025). PMID: 40147219 ↗

    L1SR_OBSCited in: Definition and Classification, Management Overview and Indications for Treatment
  5. [5]

    Focke JK, Brokbals M, Becker J et al.. “Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review.” Journal of neurology (2025). PMID: 39812656 ↗

    L4SR_OBSCited in: Definition and Classification
  6. [6]

    Zhang X, Zhao X, Chen B et al.. “The visual outcome and efficacy of current therapies for neurosarcoidosis with anterior visual pathway involvement: A systemic review.” Journal of neuroimmunology (2025). PMID: 41043325 ↗

    L1SR_OBSCited in: Definition and Classification, Epidemiology, Clinical Features and Organ Involvement, Management Overview and Indications for Treatment, Prognosis and Long-term Outcomes
  7. [7]

    Hajsadeghi S, Piryaie E, Mirshafiee S. “Isolated cardiac sarcoidosis: A systematic review.” The Journal of international medical research (2025). PMID: 41193496 ↗

    L4SR_OBSCited in: Definition and Classification, Epidemiology, Prognosis and Long-term Outcomes
  8. [8]

    Bhattacharyya S. “Neurologic Manifestations of Rheumatologic Disease.” Continuum (Minneapolis, Minn.) (2026). PMID: 41631904 ↗

    L5CASE_REPORTCited in: Definition and Classification, Etiology and Pathogenesis, Diagnosis and Diagnostic Workup, Organ-Specific Management
  9. [9]

    Tersalvi G, Rossi VA, Hundertmark M et al.. “Diagnostic challenges in isolated cardiac sarcoidosis.” ESC heart failure (2026). PMID: 42234828 ↗

    L5REVIEW_NARRATIVECited in: Definition and Classification, Clinical Features and Organ Involvement, Diagnosis and Diagnostic Workup, Organ-Specific Management
  10. [10]

    Sovani B, Ravindra SG, Javidan C et al.. “18F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.” Seminars in nuclear medicine (2026). PMID: 42225514 ↗

    L5REVIEW_NARRATIVECited in: Definition and Classification, Diagnosis and Diagnostic Workup, Organ-Specific Management
  11. [11]

    Hashim Z, Baughman RP, Agarwal R et al.. “Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.” Respiratory medicine (2026). PMID: 42144146 ↗

    L1SR_OBSCited in: Epidemiology, Organ-Specific Management
  12. [12]

    Kotti N, Kchaou A, Feki W et al.. “Occupational exposure to toxic particles and risk of pulmonary sarcoidosis: a systematic review and meta-analysis.” BMJ open respiratory research (2026). PMID: 41963075 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Pathogenesis, Organ-Specific Management
  13. [13]

    Bollano E, Fu M, Pivodic A et al.. “Increased Mortality and Morbidity in Patients With Heart Failure With Sarcoidosis Compared With Other Causes: A Propensity-Matched Nationwide Cohort Study.” Journal of the American Heart Association (2025). PMID: 41025468 ↗

    L2COHORTCited in: Epidemiology, Prognosis and Long-term Outcomes
  14. [14]

    Hodkinson EC, Quininir L, Hsiao E et al.. “Atrial Arrhythmias in Cardiac Sarcoidosis-Case Presentation and Systematic Review.” Pacing and clinical electrophysiology : PACE (2025). PMID: 41004249 ↗

    L4SR_OBSCited in: Epidemiology
  15. [15]

    Maury A, Hadjadj J, Brézin A et al.. “Uveitis Characteristics and Risk of Developing Central Nervous System Inflammatory Disease: A Retrospective Cohort Study.” Ocular immunology and inflammation (2026). PMID: 41569740 ↗

    L2COHORTCited in: Epidemiology, Special Populations
  16. [16]

    Mahmoud AK, Kamel I, Awad K et al.. “The Role of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Sarcoid Cardiomyopathy: A Multicenter Retrospective Cohort Study.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2025). PMID: 41400906 ↗

    L2COHORTCited in: Epidemiology, Special Populations
  17. [17]

    Gussek P, Mentzel J, Ablefoni M et al.. “Soluble IL-2 receptor levels support diagnosis of sarcoidosis-like reaction in melanoma patients on immunotherapy - a diagnostic algorithm based on a single center retrospective study.” Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2025). PMID: 40887791 ↗

    L3COHORTCited in: Epidemiology
  18. [18]

    Martella S, Cusumano G, Stylianakis D et al.. “When immunity backfires: Meta-analysis on sarcoidosis reactivation in cancer patients treated with immune checkpoint inhibitors.” Critical reviews in oncology/hematology (2026). PMID: 41865918 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Pathogenesis
  19. [19]

    Block B, Mehta J, Soto-Canetti G et al.. “Association Between Type I Interferonopathies and the Development of Cutaneous Sarcoidosis, Morphea, Lichen Planus and Granuloma Annulare: A Retrospective Cohort Study.” Experimental dermatology (2026). PMID: 42266012 ↗

    L2COHORTCited in: Etiology and Pathogenesis, Special Populations
  20. [20]

    Barbella G, Antenucci P, Rosa M et al.. “Neurosarcoidosis-like reaction under TNF-α inhibitors: a case report and literature review of a paradoxical immune phenomenon.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41838193 ↗

    L4CASE_REPORTCited in: Etiology and Pathogenesis, Pharmacologic Therapy, Organ-Specific Management
  21. [21]

    Li L, Liu Y, Liu J et al.. “Parathyroid-independent hypercalcemia as initial presentation of renal sarcoidosis with granulomatous interstitial nephritis: a case report.” Frontiers in endocrinology (2026). PMID: 41641029 ↗

    L4CASE_REPORTCited in: Etiology and Pathogenesis
  22. [22]

    Yasui K, Yashiro M. “Drug-induced sarcoidosis-like reaction following IL-4/IL-13 receptor blockade by dupilumab.” European journal of pediatrics (2026). PMID: 42126659 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Pathogenesis, Special Populations
  23. [23]

    Zhao R, Xi NM, Gabby L et al.. “New proteomic biomarkers identified in plasma extracellular vesicles in sarcoidosis: a case-control matched study.” Frontiers in immunology (2026). PMID: 42079598 ↗

    L3CASE_CONTROLCited in: Etiology and Pathogenesis
  24. [24]

    Dhar A, Kitani A, Strober W. “Immunological analysis of Blau syndrome, a unique autoinflammatory state.” Frontiers in immunology (2026). PMID: 42039171 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Pathogenesis, Organ-Specific Management
  25. [25]

    Bukhari S, Sheikh FH, Kelle S et al.. “Clinical and imaging profiling of restrictive cardiomyopathies: insights into amyloid, sarcoid, and iron overload phenotypes.” Heart failure reviews (2026). PMID: 41896355 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Pathogenesis, Clinical Features and Organ Involvement, Organ-Specific Management
  26. [26]

    Rizzi L, Larizza G, Suppressa P. “Exploring microbial signatures in sarcoidosis: etiological and therapeutic implications of host-microbiota interactions.” Frontiers in immunology (2026). PMID: 41685316 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Pathogenesis, Clinical Features and Organ Involvement
  27. [27]

    Wu D, Matsuda T, Xie D et al.. “NOD2-Related Multisystem Inflammatory Disorders and Recent Advances.” Current rheumatology reports (2026). PMID: 41678017 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Pathogenesis
  28. [28]

    Miedema J, Nunes H, Dalm VASH et al.. “Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment.” Autoimmunity reviews (2026). PMID: 41651390 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Pathogenesis, Differential Diagnosis
  29. [29]

    Higashida-Konishi M, Kusano S, Tabata H et al.. “Sarcoidosis-like reaction associated with tocilizumab in a patient with giant cell arteritis: a case based review.” Rheumatology international (2026). PMID: 42420531 ↗

    L4CASE_REPORTCited in: Etiology and Pathogenesis
  30. [30]

    Bez P, Chkolnaia Z, Aratari A et al.. “Anti-TNF Drug-Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature Review.” BioMed research international (2026). PMID: 42170754 ↗

    L4CASE_REPORTCited in: Etiology and Pathogenesis
  31. [31]

    James WE, Chandler J, Benfield K et al.. “A mHealth app for sarcoidosis-associated fatigue: a feasibility randomized control trial.” Respiratory medicine (2025). PMID: 41270938 ↗

    L1RCTCited in: Clinical Features and Organ Involvement
  32. [32]

    Tahmaz T, Aslan GK, Yeldan İ et al.. “Comparison of the effects of one-legged and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis.” Respiratory medicine (2025). PMID: 41015397 ↗

    L1RCTCited in: Clinical Features and Organ Involvement, Management Overview and Indications for Treatment, Prognosis and Long-term Outcomes
  33. [33]

    Herman M, Russell K, Shi H et al.. “Neurosarcoidosis of the hypothalamus, infundibulum, and pituitary gland: A retrospective cohort study.” Journal of the neurological sciences (2026). PMID: 41690183 ↗

    L3COHORTCited in: Clinical Features and Organ Involvement, Diagnosis and Diagnostic Workup, Organ-Specific Management, Special Populations
  34. [34]

    Kancerek J, Świerczek D, Baron W et al.. “Unmasking Cardiac Sarcoidosis: Integrating Multimodal Imaging with Histochemical and Ultrastructural Analysis.” International journal of molecular sciences (2026). PMID: 41977156 ↗

    L5REVIEW_NARRATIVECited in: Clinical Features and Organ Involvement, Organ-Specific Management
  35. [35]

    Ntiamoah P, Wireko F, Wagh A et al.. “Scoping out sarcoidosis: the evolving role of bronchoscopy.” European respiratory review : an official journal of the European Respiratory Society (2026). PMID: 41708121 ↗

    L5REVIEW_NARRATIVECited in: Clinical Features and Organ Involvement
  36. [36]

    Maleszewski JJ. “A Tale of Two Myocarditides: Giant Cell Myocarditis and Sarcoidosis-A Pathologist's Review.” Archives of pathology & laboratory medicine (2025). PMID: 41435868 ↗

    L5REVIEW_NARRATIVECited in: Clinical Features and Organ Involvement, Differential Diagnosis
  37. [37]

    Ledda RE, Roberti C, Sverzellati N. “From X-rays to advanced imaging modalities in pulmonary sarcoidosis.” Current opinion in immunology (2025). PMID: 41406556 ↗

    L5REVIEW_NARRATIVECited in: Clinical Features and Organ Involvement
  38. [38]

    Voortman M, Raasing L, Burggraaff J et al.. “Small Fiber Neuropathy in Sarcoidosis.” Seminars in respiratory and critical care medicine (2025). PMID: 41218636 ↗

    L5REVIEW_NARRATIVECited in: Clinical Features and Organ Involvement
  39. [39]

    Alam M, Caplan AS, Rosenbach M. “When granulomatous inflammation becomes visible: insights into cutaneous sarcoidosis.” Current opinion in immunology (2025). PMID: 41046794 ↗

    L5REVIEW_NARRATIVECited in: Clinical Features and Organ Involvement
  40. [40]

    Yoshida S, Temmoku J, Saito K et al.. “Cutaneous sarcoidosis following complete remission of diffuse large B-cell lymphoma: a case report and literature review.” Immunological medicine (2025). PMID: 41160623 ↗

    L4CASE_REPORTCited in: Clinical Features and Organ Involvement, Differential Diagnosis
  41. [41]

    Qannus AA, Özpolat HT, Salazar D et al.. “Recurrent sarcoidosis in a transplanted kidney: A case report and literature review.” Transplant immunology (2025). PMID: 40967514 ↗

    L4CASE_REPORTCited in: Clinical Features and Organ Involvement
  42. [42]

    Zheng J, Sun J. “Blau syndrome with atrophoderma vermiculata-like appearance: a case report.” Frontiers in immunology (2026). PMID: 41859084 ↗

    L4CASE_REPORTCited in: Clinical Features and Organ Involvement
  43. [43]

    Leite GW, Fonseca EKUN, Chate RC et al.. “Silicosis, Sarcoidosis, and Silicosarcoidosis Are Overlapping Diagnoses and Difficult to Differentiate.” American journal of industrial medicine (2026). PMID: 41691440 ↗

    L4CASE_REPORTCited in: Clinical Features and Organ Involvement, Diagnosis and Diagnostic Workup, Differential Diagnosis
  44. [44]

    Hsu J, Schoedel K, Plotzker A et al.. “Case of a 35-Year-Old Man With Pain With Sneezing and Leg Weakness Causing Collapse.” Annals of clinical and translational neurology (2026). PMID: 41589670 ↗

    L4CASE_REPORTCited in: Clinical Features and Organ Involvement
  45. [45]

    Zhen Y, Liang X, Huang D et al.. “Case Report: Exploring the underlying mechanisms of psoriasis comorbid with sarcoidosis: insights from a case of coexisting immune-related disorders.” Frontiers in immunology (2025). PMID: 41357198 ↗

    L4CASE_REPORTCited in: Clinical Features and Organ Involvement, Pharmacologic Therapy
  46. [46]

    Gros C, Hankiewicz K, Carle A et al.. “Case Report: Necrotizing granulomas in the central nervous system: sarcoidosis masquerading as neurotuberculosis.” Frontiers in immunology (2025). PMID: 41246339 ↗

    L4CASE_REPORTCited in: Clinical Features and Organ Involvement
  47. [47]

    Van Den Blink B, Birring SS, Mogulkoc N et al.. “Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.” The European respiratory journal (2026). PMID: 41819539 ↗

    L1RCTCited in: Diagnosis and Diagnostic Workup, Management Overview and Indications for Treatment, Organ-Specific Management, Prognosis and Long-term Outcomes, Special Populations
  48. [48]

    Rosenbaum AN, Wagle A, Meuth CL et al.. “Leveraging Interleukin-1 Blockade as a Therapeutic Strategy for Cardiac Sarcoidosis: Rationale and Design for the RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS).” Journal of cardiac failure (2026). PMID: 42128581 ↗

    L5TRIAL_NONRANDOMCited in: Diagnosis and Diagnostic Workup, Management Overview and Indications for Treatment, Organ-Specific Management, Prognosis and Long-term Outcomes
  49. [49]

    Bomhof G, Verhave J, Stegeman C et al.. “A retrospective multicenter cohort study of patients with sarcoidosis and renal involvement.” BMC nephrology (2026). PMID: 41578220 ↗

    L3COHORTCited in: Diagnosis and Diagnostic Workup, Pharmacologic Therapy, Special Populations
  50. [50]

    Nowak N, Farishta A, Chang R et al.. “Early Calciphylaxis Mimicking Infection in a Patient With End-Stage Renal Disease and Sarcoidosis: A Diagnostic and Wound Management Challenge.” International wound journal (2026). PMID: 42036346 ↗

    L4CASE_REPORTCited in: Diagnosis and Diagnostic Workup, Differential Diagnosis
  51. [51]

    Wang Y, Yu XJ, Zhang Z. “Potential benefits of JAK inhibitor therapy in Blau syndrome: a case report.” Frontiers in immunology (2026). PMID: 41601685 ↗

    L4CASE_REPORTCited in: Diagnosis and Diagnostic Workup, Prognosis and Long-term Outcomes
  52. [52]

    Tomos I, Vourli G, Matthaiou AM et al.. “Decoding sarcoidosis chronicity through phenotypic profiling.” Therapeutic advances in respiratory disease (2026). PMID: 42363565 ↗

    L3OTHERCited in: Diagnosis and Diagnostic Workup, Prognosis and Long-term Outcomes
  53. [53]

    Schett A, Gabriel A, Tascilar K et al.. “Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes.” Acta dermato-venereologica (2026). PMID: 42328997 ↗

    L4OTHERCited in: Diagnosis and Diagnostic Workup, Pharmacologic Therapy, Prognosis and Long-term Outcomes
  54. [54]

    Wopperer SB, Kronzer E, Ivare J et al.. “FDG PET for cardiac sarcoidosis: Protocol optimization, quantification, pitfalls, and multimodality imaging integration.” Seminars in nuclear medicine (2026). PMID: 42168054 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Diagnostic Workup, Organ-Specific Management
  55. [55]

    Maeda D, Fujimoto Y, Nabeta T et al.. “Positive Endomyocardial Biopsy in Cardiac Sarcoidosis: Predictors and Outcomes From the Japanese ILLUMINATE-CS (Illustration of the Management and prognosis of JapaNese PATiEnts with Cardiac Sarcoidosis) Registry.” Journal of cardiac failure (2026). PMID: 42128577 ↗

    L2OTHERCited in: Diagnosis and Diagnostic Workup
  56. [56]

    Ungprasert P, Moss BP. “Sarcoidosis of the nervous system: a rare but serious manifestation.” Current opinion in immunology (2025). PMID: 41365240 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  57. [57]

    Wagle AA, Kuzma I, Gilotra NA. “Top 7 Diagnostic Dilemmas in Cardiac Sarcoidosis: Lessons from Clinical Practice.” Seminars in respiratory and critical care medicine (2025). PMID: 41285391 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  58. [58]

    Bączek K, Piotrowski WJ, Bonella F. “Challenges in diagnosis of sarcoidosis.” Current opinion in immunology (2025). PMID: 40902264 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  59. [59]

    Pasini RA, Al-Ani MAZ, Altmayer S et al.. “Multimodality Imaging for the Diagnosis and Evaluation of Pulmonary Sarcoidosis.” Radiology. Cardiothoracic imaging (2025). PMID: 40047549 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  60. [60]

    Kahlmann V, Janssen Bonás M, Moor CC et al.. “First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate.” The New England journal of medicine (2025). PMID: 40387020 ↗

    L1TRIAL_NONRANDOMCited in: Management Overview and Indications for Treatment, Pharmacologic Therapy, Landmark Trials and Key Evidence
  61. [61]

    Gomez H, Noël N, Schmidt J et al.. “Comparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study.” Journal of neurology (2025). PMID: 40702280 ↗

    L2COHORTCited in: Management Overview and Indications for Treatment, Pharmacologic Therapy, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence
  62. [62]

    Hutto SK, Balaban D, Rohm Z et al.. “Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: a multi-center retrospective study.” Journal of neurology (2025). PMID: 40681720 ↗

    L2COHORTCited in: Management Overview and Indications for Treatment, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence
  63. [63]

    Hu Y, Li P, Liu J et al.. “Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China.” The Journal of rheumatology (2025). PMID: 40233998 ↗

    L2COHORTCited in: Management Overview and Indications for Treatment
  64. [64]

    Mahmood A, Raja MF, Imran H et al.. “TNF alpha Inhibitors in Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis.” Critical pathways in cardiology (2024). PMID: 39774535 ↗

    L1SR_OBSCited in: Pharmacologic Therapy
  65. [65]

    Alipour P, Nery PB, Beanlands RS et al.. “Durable remission of cardiac sarcoidosis following discontinuation of methotrexate: A prospective cohort study.” Respiratory medicine (2025). PMID: 40316030 ↗

    L2COHORTCited in: Pharmacologic Therapy, Landmark Trials and Key Evidence
  66. [66]

    Lequain H, Streichenberger N, Gallay L et al.. “Granulomatous myositis: characteristics and outcome from a monocentric retrospective cohort study.” Neuromuscular disorders : NMD (2024). PMID: 39059057 ↗

    L2COHORTCited in: Pharmacologic Therapy, Landmark Trials and Key Evidence
  67. [67]

    Hütter G, Winkelhausen M, Tönges L et al.. “Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease - case report.” Frontiers in immunology (2026). PMID: 42305552 ↗

    L4CASE_REPORTCited in: Pharmacologic Therapy
  68. [68]

    Shen J, Sugita M, Linares-Lopez A et al.. “Adalimumab as treatment for neurosarcoidosis: A case series.” Journal of the neurological sciences (2024). PMID: 38640580 ↗

    L4CASE_REPORTCited in: Pharmacologic Therapy
  69. [69]

    Drakopanagiotakis F, Papanikolaou I, Panou T et al.. “New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.” International journal of molecular sciences (2026). PMID: 42353055 ↗

    L5REVIEW_NARRATIVECited in: Pharmacologic Therapy
  70. [70]

    Nteris O, Verghese E, Nguyen QA et al.. “Extracellular vimentin promotes neutrophil-dominant granulomatous inflammation in progressive pulmonary sarcoidosis.” Clinical science (London, England : 1979) (2026). PMID: 42084847 ↗

    L5OTHERCited in: Pharmacologic Therapy
  71. [71]

    Nishimura T, Ishibashi K, Kanaoka K et al.. “Prognostic impact of corticosteroid maintenance dose and re-escalation in patients with cardiac sarcoidosis.” Open heart (2026). PMID: 41791843 ↗

    L2OTHERCited in: Pharmacologic Therapy
  72. [72]

    Harper LJ, Baughman RP, Lower EE et al.. “Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.” Chest (2025). PMID: 41412223 ↗

    L4OTHERCited in: Pharmacologic Therapy
  73. [73]

    Queisi MM, Pardo CA. “Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.” Seminars in respiratory and critical care medicine (2025). PMID: 41371265 ↗

    L5REVIEW_NARRATIVECited in: Pharmacologic Therapy
  74. [74]

    Chkolnaia Z, Lebrun-Vignes B, Amiot A et al.. “TNF Inhibitor-Induced Sarcoidosis-Like Lesions in Inflammatory Bowel Disease.” United European gastroenterology journal (2025). PMID: 41358635 ↗

    L4OTHERCited in: Pharmacologic Therapy
  75. [75]

    Cattran A, Culver DA. “Treatment of Sarcoidosis Over the Next Decade.” Seminars in respiratory and critical care medicine (2025). PMID: 41237809 ↗

    L5REVIEW_NARRATIVECited in: Pharmacologic Therapy
  76. [76]

    Miedema JR, Bonella F, Buschulte K et al.. “Sarcoidosis: a state-of-the-art review.” The European respiratory journal (2026). PMID: 41232941 ↗

    L5REVIEW_NARRATIVECited in: Pharmacologic Therapy
  77. [77]

    Donnelly R, Boyle N, McCarthy C et al.. “FDG PET in pulmonary sarcoidosis: An update and future aspects.” Seminars in nuclear medicine (2026). PMID: 41936480 ↗

    L5REVIEW_NARRATIVECited in: Organ-Specific Management
  78. [78]

    Tan Y, Wang Y, Liu X et al.. “Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer.” Frontiers in immunology (2025). PMID: 40607429 ↗

    L4CASE_REPORTCited in: Prognosis and Long-term Outcomes
  79. [79]

    Dadson P, Ylä-Outinen H, Kalliokoski K et al.. “Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [68Ga]Ga-DOTA-Siglec-9.” Respiratory research (2025). PMID: 41420234 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  80. [80]

    Drew Z, Xie BY, Sivaratnam D et al.. “Complementary Roles of Cardiac MRI and FDG-PET/CT in the Evaluation of Cardiac Sarcoidosis: Insights From a Single-Centre Retrospective Study.” Journal of medical imaging and radiation oncology (2025). PMID: 41399919 ↗

    L4COHORTCited in: Special Populations
  81. [81]

    Tsukao H, Sawahata M, Arai N et al.. “Immune-mediated inflammatory diseases associated with sarcoidosis: A case-control study in Japan.” Respiratory medicine (2025). PMID: 41319839 ↗

    L3CASE_CONTROLCited in: Special Populations
  82. [82]

    Nolte JYC, Ten Dam L, van de Beek D et al.. “Clinical characteristics and outcome of neurosarcoidosis-associated myelitis: A retrospective cohort study and review of the literature.” European journal of neurology (2022). PMID: 35189010 ↗

    L3SR_OBSCited in: Landmark Trials and Key Evidence
  83. [83]

    Baker MC, Horomanski A, Wang Y et al.. “A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.” Rheumatology (Oxford, England) (2024). PMID: 37471590 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  84. [84]

    Morimoto R, Unno K, Fujita N et al.. “Prospective Analysis of Immunosuppressive Therapy in Cardiac Sarcoidosis With Fluorodeoxyglucose Myocardial Accumulation: The PRESTIGE Study.” JACC. Cardiovascular imaging (2023). PMID: 37452820 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  85. [85]

    Mahevas M, Audard V, Rousseau A et al.. “Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36066903 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  86. [86]

    Sakkat A, Cox G, Khalidi N et al.. “Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis.” Respiratory research (2022). PMID: 35264154 ↗

    L3RCTCited in: Landmark Trials and Key Evidence
  87. [87]

    Rossides M, Kullberg S, Di Giuseppe D et al.. “Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective 'target trial' emulated with Swedish real-world data.” Respirology (Carlton, Vic.) (2021). PMID: 33398914 ↗

    L3RCTCited in: Landmark Trials and Key Evidence
  88. [88]

    Vis R, van de Garde EMW, Meek B et al.. “Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis.” Respiratory medicine (2020). PMID: 32308204 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  89. [89]

    Kahlmann V, Janssen Bonás M, Moor CC et al.. “Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study.” BMC pulmonary medicine (2020). PMID: 33076885 ↗

    L5RCTCited in: Landmark Trials and Key Evidence
  90. [90]

    Rivière E, Jourde W, Gensous N et al.. “Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients.” Respiratory research (2024). PMID: 38486260 ↗

    L3COHORTCited in: Landmark Trials and Key Evidence
  91. [91]

    Bergner R, Weiner SM, Kehl G et al.. “Renal disease in sarcoidosis patients in a German multicentric retrospective cohort study.” Respiratory medicine (2023). PMID: 36669705 ↗

    L3COHORTCited in: Landmark Trials and Key Evidence
  92. [92]

    Baughman RP, Valeyre D, Korsten P et al.. “ERS clinical practice guidelines on treatment of sarcoidosis.” The European respiratory journal (2021). PMID: 34140301 ↗

    L1GUIDELINECited in: Guidelines and Resources
  93. [93]

    Crouser ED, Maier LA, Wilson KC et al.. “Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2020). PMID: 32293205 ↗

    L1GUIDELINECited in: Guidelines and Resources
  94. [94]

    Wahidi MM, Herth F, Yasufuku K et al.. “Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report.” Chest (2016). PMID: 26402427 ↗

    L1GUIDELINECited in: Guidelines and Resources
  95. [95]

    Lo KH, Donohue J, Judson MA et al.. “The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis.” Lung (2020). PMID: 32979072 ↗

    L2RCTCited in: Guidelines and Resources
  96. [96]

    Zhou Y, Lower EE, Li HP et al.. “Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival.” Chest (2016). PMID: 27614001 ↗

    L3TRIAL_NONRANDOMCited in: Guidelines and Resources
  97. [97]

    Drent M, Cremers JP, Jansen TL et al.. “Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis.” Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG (2014). PMID: 25078637 ↗

    L5GUIDELINECited in: Guidelines and Resources
  98. [98]

    Van Woensel J, Koopman B, Schiefer M et al.. “Organ involvement in newly diagnosed sarcoidosis patients in the Netherlands: The first large European multicentre prospective study.” Respiratory medicine (2024). PMID: 38582302 ↗

    L2COHORTCited in: Guidelines and Resources
  99. [99]

    Lundkvist A, Kullberg S, Arkema EV et al.. “Differences in disease presentation between men and women with sarcoidosis: A cohort study.” Respiratory medicine (2021). PMID: 34839065 ↗

    L3COHORTCited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…